Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents

Psychopharmacology

Volumn 191, Issue 1, 2007, Pages 127-140

  Ipser, Jonathan ^a   Stein, Dan J ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Conduct disorder; Disruptive behavior disorders; Impulse control disorders; Metaanalysis; Oppositional defiant disorder; Pediatric; Pharmacotherapy; Systematic review

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CARBAMAZEPINE; CLONIDINE; DIPHENHYDRAMINE; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; MOLINDONE; MOOD STABILIZER; PEMOLINE; PHENYTOIN; PLACEBO; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRAZODONE; VALPROATE SEMISODIUM;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; ANOREXIA; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; COMORBIDITY; DECREASED APPETITE; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DISTRESS SYNDROME; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; IMPULSE CONTROL DISORDER; INCREASED APPETITE; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NAUSEA; OPPOSITIONAL DEFIANT DISORDER; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT PSYCHOLOGY; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD PSYCHOLOGY; HUMANS; LITHIUM COMPOUNDS; PATIENT SELECTION; PSYCHOTROPIC DRUGS; RISK ASSESSMENT; RISPERIDONE; TREATMENT OUTCOME;

EID: 33847163581     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0537-6     Document Type: Review

References (80)

1. Alcantara AG, Barcia D (1999) Risperidone and concept of bipolar neuroleptic (in French). Encephale 25:146-150
2. Aman MG, Binder C, Turgay A (2002a) Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243-254
3. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (2002b) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346
4. Aman MG, Binder C, Turgay A (2004) Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243-254
5. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Association, Washington, DC
6. Askenazy FL, Sorci K, Benoit M, Lestideau K, Myquel M, Lecrubier Y (2003) Anxiety and impulsivity levels identify relevant subtypes in adolescents with at-risk behavior. J Affect Disord 74:219-227
7. Banaschewski T, Brandeis D, Heinrich H, Albrecht B, Brunner E, Rothenberger A (2003) Association of ADHD and conduct disorder - brain electrical evidence for the existence of a distinct subtype. J Child Psychol Psychiatry 44:356-376
8. Barker P, Fraser IA (1968) A controlled trial of haloperidol in children. Br J Psychiatry 114:855-857
9. Biederman J, Faraone SV, Milberger S, Jetton JG, Chen L, Mick E, Greene RW, Russell RL (1996) Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 35:1193-1204
10. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248
11. Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ (2003) Conduct disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 13:305-311
12. Burke JD, Loeber R, Birmaher B (2002) Oppositional defiant disorder and conduct disorder: a review of the past 10 years, part II. J Am Acad Child Adolesc Psychiatry 41:1275-1293
13. Campbell M, Small AM, Green WH, Jennings SJ, Perry R, Bennett WG, Anderson L (1984) Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650-656
14. Campbell M, Adams PB, Small AM, Kafantaris V, Silva RR, Shell J, Perry R, Overall JE (1995) Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 34:445-453
15. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, Poulton R (8-2-2002) Role of genotype in the cycle of violence in maltreated children. Science 297:851-854
16. Cherek DR, Lane SD, Pietras CJ, Steinberg JL (2002) Effects of chronic paroxetine administration on measures of aggressive and impulsive responses of adult males with a history of conduct disorder. Psychopharmacology (Berl) 159:266-274
17. Coccaro EF, Danehy M (2006) Intermittent explosive disorder. In: Hollander E, Stein DJ (eds) Clinical manual of impulse-control disorders. American Psychiatric Publishers, Arlington, pp 19-37
18. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale, NJ
19. Connor DF, Barkley RA, Davis HT (2000) A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 39:15-25
20. Connor DF, Fletcher KE, Wood JS (2001) Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62:967-974
21. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr (2002) Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 41:253-261
22. Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M (1996) Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 35:480-490
23. Cunningham MA, Pillai V, Rogers WJ (1968) Haloperidol in the treatment of children with severe behaviour disorders. Br J Psychiatry 114:845-854
24. Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH (2002) Conduct problems, gender and adult psychiatric outcome of children with attention-deficit hyperactivity disorder. Br J Psychiatry 181:416-421
25. Deeks J, Higgins J, Altman D (2005) Analysing and presenting results. Cochrane handbook for systematic reviews of interventions 4.2.5 (updated May 2005). Section 8. In: Deeks J, Higgins J, Altman D (eds) The Cochrane Library, Issue 3. Wiley, Chichester, UK
26. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
27. Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel W, Susser E, Klein DF (2000) Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 157:818-820
28. Fergusson DM, Horwood LJ, Ridder EM (2005) Show me the child at seven: the consequences of conduct problems in childhood for psychosocial functioning in adulthood. J Child Psychol Psychiatry 46:837-849
29. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516
30. Fischer M, Barkley RA (2003) Childhood stimulant treatment and risk for later substance abuse. J Clin Psychiatry 64(Suppl 11):19-23
31. Foley HA, Carlton CO, Howell RJ (1996) The relationship of attention deficit hyperactivity disorder and conduct disorder to juvenile delinquency: legal implications. Bull Am Acad Psychiatry Law 24:333-345
32. Gadow KD, Nolan EE, Sverd J, Sprafkin J, Paolicelli L (1990) Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry 29:710-718
33. Greenhill LL, Solomon M, Pleak R, Ambrosini P (1985) Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 46:20-25
34. Hart EL, Lahey BB, Loeber R, Hanson KS (1994) Criterion validity of informants in the diagnosis of disruptive behavior disorders in children: a preliminary study. J Consult Clin Psychol 62:410-414
35. Hazell PL, Stuart JE (2003) A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 42:886-894
36. Hazell PL, McDowell MJ, Walton JM (1996) Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of NSW. Med J Aust 165:477-480
37. Hollander E, Baker BR, Kahn J, Stein DJ (2006) Conceptualizing and assessing impulse-control disorders. In: Hollander E, Stein DJ (eds) Clinical manual of impulse-control disorders. American Psychiatric Publishing, Arlington, pp 1-18
38. Jaffee SR, Caspi A, Moffitt TE, Dodge KA, Rutter M, Taylor A, Tully LA (2005) Nature X nurture: genetic vulnerabilities interact with physical maltreatment to promote conduct problems. Dev Psychopathol 17:67-84
39. Kaplan SL, Busner J, Kupietz S, Wassermann E, Segal B (1990) Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report. J Am Acad Child Adolesc Psychiatry 29:719-723
40. Kaplan SL, Simms RM, Busner J (1994) Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 33:35-44
41. Keenan K (2005) Antipsychotics in disruptive behavior disorders and ADHD. J Am Acad Child Adolesc Psychiatry 44:969-970
42. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602
43. Kim SW, Grant JE, Adson DE, Shin YC (2001) Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49:914-921
44. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S (1997) Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 54:1073-1080
45. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD, Strauss J (1994) Clinical and cognitive effects of methylphenidate on children with attention deficit disorder as a function of aggression/oppositionality and age. J Abnorm Psychol 103:206-221
46. Kolko DJ, Bukstein OG, Barron J (1999) Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry 38:578-586
47. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit/ hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11-28
48. Lahey BB, Loeber R, Burke J, Rathouz PJ (2002) Adolescent outcomes of childhood conduct disorder among clinic-referred boys: predictors of improvement. J Abnorm Child Psychol 30:333-348
49. Loeber R, Green SM, Keenan K, Lahey BB (1995) Which boys will fare worse? Early predictors of the onset of conduct disorder in a six-year longitudinal study. J Am Acad Child Adolesc Psychiatry 34:499-509
50. Loeber R, Burke JD, Lahey BB, Winters A, Zera M (2000) Oppositional defiant and conduct disorder: a review of the past 10 years, part I. J Am Acad Child Adolesc Psychiatry 39:1468-1484
51. Looker A, Conners CK (1970) Diphenylhydantoin in children with severe temper tantrums. Arch Gen Psychiatry 23:80-89
52. Malone RP, Luebbert J, Pena-Ariet M, Biesecker K, Delaney MA (1994a) The Overt Aggression Scale in a study of lithium in aggressive conduct disorder. Psychopharmacol Bull 30:215-218
53. Malone RP, Luebbert J, Pena-Ariet M, Biesecker K, Delaney MA (1994b) The Overt Aggression Scale in a study of lithium in aggressive conduct disorder. Psychopharmacol Bull 30:215-218
54. Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000) A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649-654
55. Mozes T, Meiri G, Ben Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 15:259-269
56. Newcorn JH, Halperin JM, Jensen PS, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Epstein JN, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Kraemer HC, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B (2001) Symptom profiles in children with ADHD: effects of comorbidity and gender. J Am Acad Child Adolesc Psychiatry 40:137-146
57. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D (2005) Atomoxetine treatment in children and adolescents with attention-deficit/ hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44:240-248
58. Nock MK, Kazdin AE, Hiripi E, Kessler RC (2006) Prevalence, subtypes, and correlates of DSM-IV conduct disorder in the National Comorbidity Survey Replication. Psychol Med 1-12
59. Platt JE, Campbell M, Green WH, Grega DM (1984) Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41:657-662
60. Rey JM, Walter G (1999) Oppositional defiant disorder. In: Hendren RL (ed) Disruptive behavior disorders in children and adolescents. American Psychiatric Press, Washington, DC, pp 99-132
61. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163:402-410
62. Rifkin A, Karajgi B, Dicker R, Perl E, Boppana V, Hasan N, Pollack S (1997) Lithium treatment of conduct disorders in adolescents. Am J Psychiatry 154:554-555
63. Riggs PD, Leon SL, Mikulich SK, Pottle LC (1998) An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 37:1271-1278
64. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A (2004) A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry 43:420-429
65. Robinson KA, Dickersin K (2002) Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 31:150-153
66. Rosenthal R, Rosnow RL (1991) Essentials of behavioral research: Methods and data analysis, 2nd edn. McGraw-Hill, New York
67. Satterfield JH, Schell A (1997) A prospective study of hyperactive boys with conduct problems and normal boys: adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry 36:1726-1735
68. Scott S, Knapp M, Henderson J, Maughan B (2001) Financial cost of social exclusion: follow up study of antisocial children into adulthood. BMJ 323:191
69. Serra-Pinheiro MA, Mattos P, Souza I, Pastura G, Gomes F (2004) The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Arq Neuropsiquiatr 62:399-402
70. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, Risperidone Conduct Study Group (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036
71. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R (2006) Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther 28:402-418
72. Steiner H, Karnik N (2003) Adolescent Antisocial Behavior. In: Sadock BJ, Sadock VA (eds) Comprehensive textbook of psychiatry. Williams & Wilkins, New York
73. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M (2001) Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179
74. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M (1987) Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 17:121-143
75. The Cochrane Collaboration (2005) Review manager (RevMan) version 4.2.8 for Windows. Oxford, England
76. Van Bellinghen M, De Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5-13
77. Vitacco MJ, Rogers R (2001) Predictors of adolescent psychopathy: the role of impulsivity, hyperactivity, and sensation seeking. J Am Acad Psychiatry Law 29:374-382
78. Vitiello B, Hill JL, Elia J, Cunningham E, McLeer SV, Behar D (1991) P.r.n. medications in child psychiatric patients: a pilot placebo-controlled study. J Clin Psychiatry 52:499-501
79. Waschbusch DA, Pelham WE Jr, Jennings JR, Greiner AR, Tarter RE, Moss HB (2002) Reactive aggression in boys with disruptive behavior disorders: behavior, physiology, and affect. J Abnorm Child Psychol 30:641-656
80. Zubieta JK, Alessi NE (1992) Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. J Clin Psychopharmacol 12:346-351